NCT03282695 (O3HDCIRUGIA) is a clinical trial in Lumbar Herniated Disc, sponsored by Bernardino Clavo, MD, PhD.

Who is sponsoring NCT03282695?

NCT03282695 is sponsored by Bernardino Clavo, MD, PhD.

What condition does NCT03282695 study?

NCT03282695 studies Lumbar Herniated Disc.

Is NCT03282695 still recruiting?

NCT03282695 is currently active, enrolled. Last updated 4 March 2025.

Last reviewed 2025-03-04 · How we verify

NCT03282695: O3HDCIRUGIA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ozone Therapy in Patients on Waiting List for Surgery Due to Disc Herniation: Prospective, Post-authorization Study

Active, enrolled Last updated 4 March 2025

What this trial tests

trial in Lumbar Herniated Disc in 70 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

9 March 2018

Primary endpoint
31 December 2023

31 March 2026

Quick facts

Lead sponsor	Bernardino Clavo, MD, PhD
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	70
Start date	9 March 2018
Primary completion	31 December 2023
Estimated completion	31 March 2026
Sites	1 location across Spain

Conditions studied

Lumbar Herniated Disc — all drugs for Lumbar Herniated Disc →

Sponsor

Bernardino Clavo, MD, PhD — full company profile →

Who can join

Adults 18 to 75, any sex, with Lumbar Herniated Disc. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objective of this study is to estimate the cost-effectiveness of ozone therapy in patients on the waiting list for surgery due to disc herniation.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Pain Relief, Disability, and Hospital Costs After Intradiscal Ozone Treatment or Microdiscectomy for Lumbar Disc Herniation: A 24-Month Real-World Prospective Study.
Bisshopp S, Linertová R, Caramés MA, Szolna A, et al · · 2025 · cited 1× · PMID 40648907 · DOI 10.3390/jcm14134534

Verify or expand the search:

Other Bernardino Clavo, MD, PhD trials

Trials by the same sponsor.

NCT07259681 — Gut Microbiome in Gynecological Cancer Patients With Pelvic Toxicity: Controls Versus Ozone Treatment. (MicrOzoGineTox) · not yet recruiting
NCT07325851 — Patients Referred to the Chronic Pain Unit for Palliative Treatment With Ozone Therapy Between 2026 and 2029. · not yet recruiting
NCT06816095 — Gene and Molecular Pathways of Ozone Treatment Response in Gynecological Tumor Patients With Chronic Pelvic Pain Seconda · recruiting
NCT06799351 — Gut Microbiome Profiles in Patients with Chemotherapy-induced Neuropathy in the RCT OzoParQT (NCT06706544). · Phase 2, PHASE3 · recruiting
NCT06706544 — Ozone Treatment in Paresthesia (Numbness, Tingling) Secondary to Chemotherapy-induced Peripheral Neuropathy · Phase 2, PHASE3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03282695 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bernardino Clavo, MD, PhD
Last refreshed: 4 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03282695.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing